Search Results for citation:"89 FR 106522"

The Health Resources and Services Administration (HRSA) has updated guidelines for women's preventive health services, focusing on three areas: Screening and Counseling for Intimate Partner and Domestic Violence, Breast Cancer Screening for Women at Average Risk, and Patient Navigation Services for Breast and Cervical Cancer Screening. These updates were based on recommendations from the Women's Preventive Services Initiative (WPSI) and were developed by expert health professionals. The updates aim to ensure that certain preventive health services are covered without cost-sharing by health insurance plans. For most plans, these changes will take effect in 2026.

The Food and Drug Administration (FDA) announced a correction to a previous notice regarding the withdrawal of approval for 23 abbreviated new drug applications (ANDAs). These applications, held by companies like Fosun Pharma USA Inc., Baxter Healthcare Corp., Celltrion USA, and i3 Pharmaceuticals, were initially set to be withdrawn by August 28, 2024. However, because these companies asked in time not to have their ANDAs withdrawn, the approvals remain valid. This notice clarifies the error and ensures the continued approval of these drug applications.